Milk-only Lactation Study for Patients on Eltrombopag

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2013-03-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase IV study to evaluate eltrombopag concentrations in breast milk of nursing mothers taking marketed eltrombopag (PROMACTA®). Up to 10 subjects (mother-infant pairs) at as many as 10 study centers in the US will be enrolled. Nursing mothers who are registered with the PROMACTA Pregnancy Registry will be offered the option to participate in this trial if they continue to take commercial eltrombopag post-delivery and decide to breastfeed their infant. Information will be collected in a diary. Breast milk samples will be collected before and after infant feedings for a 24 hour period after eltrombopag dosing to evaluate the eltrombopag concentrations in the breast milk. Mothers will also be given the option to have a pharmacokinetic (PK) blood sample collected from the infant.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia

NCT02690714

Hypoplasminogenemia Congenital Plasminogen Deficiency

COMPLETED PHASE2/PHASE3

A Rollover Study to Provide Continued Treatment With Eltrombopag

NCT01957176

Thrombocytopaenia

COMPLETED PHASE4

The Prospective Randomized Controlled Study of Eltrombopag on Hematopoietic Reconstruction After Allogeneic HSCT

NCT03902041

Allogeneic Hematopoietic Stem Cell Transplantation Eltrombopag

UNKNOWN

A Phase II Dose-escalation Study Characterizing the PK of Eltrombopag in Pediatric Patients With Previously Untreated or Relapsed Severe Aplastic Anemia or Recurrent Aplastic Anemia

NCT03025698

Aplastic Anemia

COMPLETED PHASE2

Role of Eltrombopag as First Line Therapy in Primary Immune Thrombocytopenia.

NCT06531018

Primary Immune Thrombocytopenia

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopaenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study

Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.

Group Type EXPERIMENTAL

eltrombopag

Intervention Type DRUG

Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

eltrombopag

Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Mother is registered with the PROMACTA Pregnancy Registry and meets all the enrollment criteria defined in the PROMACTA Pregnancy Registry study (113327).
* Mother is continuing to take eltrombopag.
* Mother has received 7 consecutive eltrombopag doses prior to the milk sample collection.
* Infant is 4 weeks to 26 weeks of age at the time of milk sampling.
* Exclusively breastfeeding mother-infant pair; either via breast or with expressed milk from the mother.
* Mother is capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

* Infant was born with complications that could impact ability to participate in this study.
* Breastfeeding is not well established in the mother-infant pair (e.g., poor latching of the infant or low milk supply).
* Infants who are supplemented with formula or are consuming solid foods.
* Unwillingness or inability of mother to follow the procedures outlined in the protocol.
* Mother is mentally or legally incapacitated

Minimum Eligible Age

4 Weeks

Maximum Eligible Age

26 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No